We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Nexstim
Getting back on the front footScancell
SCIB2 to use new nanoparticle formulationMereo BioPharma
Focus shifts back to imminent dataMaxCyte
Dosing advances to second cohort in CARMA Phase IBonesupport
Building momentumScancell
Phase II melanoma study with SCIB1 to start in Q219MaxCyte
At the forefront of the cell therapy revolutionMereo BioPharma
Path cleared for partnering of acumapimod (BCT-197)Hutchison China MediTech
Proposed listing in Hong Kong and global offeringHutchison China MediTech
AACR 2019: Savolitinib in the spotlight in NSCLC